📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. (2017)

First Author: Van Den Bent MJ

Attributed to: CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(17)31442-3

PubMed Identifier: 28801186

Publication URI: http://europepmc.org/abstract/MED/28801186

Type: Journal Article/Review

Volume: 390

Parent Publication: Lancet (London, England)

Issue: 10103

ISSN: 0140-6736